CD44 and breast carcinoma: MDA‐MB‐231 cells express high levels of the mesenchymal marker CD44 and intermediate levels of the epithelial marker CD24, a phenotype early on linked to high tumor‐initiating (or cancer stem cell) ability of patient‐derived breast cancer xenografts [25].